CONCISE REPORT

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab

Carrie L Wagner,1 Sudha Visvanathan,2 Michael Elashoff,3 Iain B McInnes,4 Philip J Mease,5 Gerald G Krueger,6 Frederick T Murphy,7 Kim Papp,8 Juan J Gomez-Reino,9 Michael Mack,10 Anna Beutler,11 Dafna Gladman,11 Arthur Kavanaugh12

ABSTRACT

Objective To determine serum biomarker associations with clinical response to golimumab treatment in patients with psoriatic arthritis (PsA).

Methods GO–REVEAL was a randomised, placebo-controlled study of golimumab in patients with active PsA. Samples were collected from 100 patients at baseline, week 4 and week 14, and analysed for serum-based biomarkers and protein profiling (total 92 markers); data were correlated with clinical measures at week 14.

Results Serum levels of a subset of proteins (apolipoprotein C III, ENRAGE, IL-16, myeloperoxidase, vascular endothelial growth factor, pyridinoline, matrix metalloproteinase 3, C-reactive protein (CRP), carcinoembryonic antigen, intercellular adhesion molecule 1 and macrophage inflammatory protein 1α) at baseline or week 4 were strongly associated with American College of Rheumatology 20% improvement (ACR20) response and/or disease activity score in 28 joints (DAS28) at week 14. A smaller subset of proteins was significantly associated with a 75% improvement in the psoriasis area and severity index score (PASI75) at week 14, (adiponectin, apolipoprotein C III, ENRAGE, IL-16, myeloperoxidase, C-reactive protein (CRP)), glutamic oxaloacetic transaminase, and tumour necrosis factor α). Subsets of proteins were identified as potentially predictive of clinical response for each of the clinical measures, and the power of these biomarker panels to predict clinical response to golimumab treatment was stronger than for CRP alone.

Conclusions This analysis provides insight into several panels of markers that may have utility in identifying PsA patients likely to have ACR20, DAS28, or PASI75 responses following golimumab treatment.

INTRODUCTION

Psoriatic arthritis (PsA) is a chronic, inflammatory joint disease involving synovial tissue, enthesis and skin,1 and is associated with elevated serum and tissue levels of markers of inflammation and bone metabolism. Some pro-inflammatory cytokines including interleukin (IL)-1, IL-6, IL-15, IL-18 and tumour necrosis factor-like weak inducer of apoptosis (TWEAK)2 have been reported to be abundantly expressed in the synovium of PsA patients.3 4 Serum levels of TWEAK were shown to correlate with matrix metalloproteinase (MMP)-3 and disease activity score in 28 joints (DAS28) using the C reactive protein (CRP) level scores in patients with PsA.5 6 Serum MMP-3 levels have been modulated following anti-tumour necrosis factor (TNF)α therapy in PsA.7 Markers of inflammation such as CRP correlated with markers of bone remodelling (C-telopeptide of type I collagen (CTX-1) and deoxypyridinoline (DPD))8 in PsA, and macrophage colony-stimulating factor and receptor activator of nuclear factor κB ligand (RANKL) have also been correlated with radiographic progression and joint space narrowing.9 These data suggest that both inflammatory and bone remodelling processes are activated in patients with active PsA.

We recently assessed the safety and efficacy of golimumab treatment (a human monoclonal antibody to TNFα) in a phase III study of active PsA.10 We sought to identify biomarkers associated with clinical progression or therapeutic response in skin and articular compartments. We analysed approximately 100 different serum proteins using multiplex and single-plex assay platforms (ELISA and Luminex) to identify markers modulated by golimumab treatment in patients with active PsA. Comparisons of baseline markers, along with change from baseline to week 4, were evaluated against several clinical response measures including the American College of Rheumatology 20% improvement (ACR20) response, DAS28 and 75% improvement in the psoriasis area and severity index score (PASI75), which assesses response of skin lesions, with the intent to understand the relationships between the markers and specific aspects of PsA.

MATERIALS AND METHODS

The primary results of the GO–REVEAL trial have previously been published.9 Briefly, adult patients with active PsA, despite previous therapy with disease-modifying antirheumatic drugs or non-steroidal anti-inflammatory drugs, were enrolled in this study. Patients were assigned in a ratio of 1:1.5:1.3 to receive subcutaneous injections of
placebo (n=113), golimumab 50 mg (n=146), or golimumab 100 mg (n=146) every 4 weeks through week 20. For this analysis, the golimumab groups were combined into a single group and compared against the placebo group. The primary endpoint was the proportion of patients with ACR20 response at week 14, DAS28 using CRP—see primary paper and PASI75 were secondary endpoints.10

In this prospectively planned GO–REVEAL biomarker substudy, analyses were conducted for the first 100 patients, at selected study sites, who had sera obtained at weeks 0, 4 and 14. The evaluated markers were chosen based on biomarker publications in PsA and previous experience in TNF-mediated autoimmune diseases including rheumatoid arthritis (RA) and PsA. Specific individual markers were chosen as well as a Rules Based Medicine Human MAP panel of markers and all assays met a variety of assay validation criteria. Serum was collected by standard methods and frozen at −70°C at the site before shipment to the central and specialty laboratories for batched testing. Samples were tested by Quintiles Laboratories (Manetta, Georgia, USA), Pacific Biomarkers (Seattle, Washington, USA) and Rules Based Medicine (Austin, Texas, USA); data were sent to Elashoff Consulting (Redwood City, California, USA) for statistical analysis. All 92 biomarkers had a lower limit of quantification and met specified data inclusion criteria (eg, ≥20% of all samples for a given marker had to be above the lower limit of quantification for that assay). Biomarkers that were undetectable at baseline were excluded from subsequent data analyses. Robust linear regression models were used to test for the association of combined biomarker panels with multiple clinical endpoints. To account for multiple statistical testing, a false discovery rate (FDR) analysis was performed. The FDR analysis was used to define a p value threshold at which the FDR would be approximately 5–10%, and accounts for the fact that the biomarkers studied were not independent as demonstrated by marker-to-marker correlations. Prediction models were developed using logistic regression methods. The criteria for inclusion of data and statistical analysis methods were recently described in two similar golimumab biomarker studies.11 12

RESULTS

Of the 92 analytes, 30 markers were not detectable at baseline and 62 met the criterion for inclusion and were analysed further. Overall, baseline biomarker levels were similar between the placebo and golimumab treatment groups and only four markers (brain-derived neurotrophic factor, insulin, TNF RII and intercellular adhesion molecule (ICAM)-1) were significantly different between the placebo and golimumab treatment groups at baseline (data not shown).

Biomarker changes over time

In the golimumab-treated group, multiple markers showed significant change from baseline to week 4. Figure 1 shows a heat map representation of markers in which the mean change from baseline at weeks 4 or 14 was significantly different between the two treatment groups. In general, golimumab treatment decreased levels of many biomarkers from baseline to week 14, with stable or slightly increasing levels of markers in the placebo group. In golimumab-treated patients, the levels of acute phase reactants (serum amyloid P, haptoglobin, α1 antitrypsin), inflammatory markers (monocyte/macrophage derived chemokine, macrophage inflammatory protein (MIP)-1β, IL-8, IL-16, ENRAGE (also known as S100A12), ICAM-1, MMP-3, Monocyte chemotactic protein-1 (MCP-1), vascular endothelial growth factor (VEGF), and other proteins (PAI-1, thyroxine binding globulin) were significantly decreased at weeks 4 and 14 compared with placebo-treated patients. Golimumab

### Table 1 Baseline demographics

|                       | Placebo     | Golimumab 50 mg | Golimumab 100 mg | Combined golimumab |
|-----------------------|-------------|-----------------|------------------|--------------------|
| Overall population    |             |                 |                  |                    |
| n                     | 113         | 146             | 146              | 292                |
| Age (years)           | 47 (40, 54) | 44 (38, 54)     | 50 (39, 56)      | 47 (38.5, 55)      |
| Weight (kg)           | 86.3 (70, 96.8) | 80.7 (69.3, 94.3) | 84.6 (71.6, 99.2) | 82.9 (70.2, 96.9)  |
| Sex (% male)          | 61%         | 61%             | 59%              | 60%                |
| Race (% Caucasian)    | 97%         | 97%             | 97%              | 97%                |
| CRP (mg/ml)           | 0.6 (0.3, 1.3) | 0.6 (0.3, 1.6)   | 0.6 (0.3, 1.7)   | 0.6 (0.3, 1.6)     |
| Methotrexate usage (% yes) | 48%        | 49%            | 47%              | 48%                |
| Swollen joint count   | 13.4±9.8    | 14.1±11.4       | 12±8.5           | 13±10.1            |
| Tender joint count    | 21.9±14.7   | 24±17.1         | 22.5±15.7        | 23.3±16.4          |
| PASI                  | 6.52±6.83   | 7.85±8.14       | 8.76±9.13        | 7.81±8.22          |
| Biomarker substudy population |           |                 |                  |                    |
| N                     | 26          | 39              | 35               | 74                 |
| Age (years)           | 42.5 (36, 53.5) | 47 (41, 52.5)     | 52 (43, 56.5)     | 48.5 (42, 55.8)    |
| Weight (kg)           | 87.3 (71.2, 96.8) | 88 (78.2, 103.5) | 95.4 (76.4, 104.7) | 90 (79, 104)       |
| Sex (% male)          | 54%         | 67%             | 60%              | 64%                |
| Race (% Caucasian)    | 96%         | 92%             | 94%              | 93%                |
| CRP (µg/ml)           | 0.6 (0.3, 1.3) | 0.6 (0.3, 1.2)   | 0.9 (0.4, 2.1)   | 0.6 (0.3, 1.4)     |
| Methotrexate usage (% yes) | 38%        | 32%            | 37%              | 35%                |
| Swollen joint count   | 11.8±8.7    | 12±7.4          | 10.3±4.9         | 11.7±6.4           |
| Tender joint count    | 20.7±12.5   | 21.1±13         | 21±10.5          | 21.1±11.8          |
| PASI                  | 5.67±4.26   | 7.77±6.38       | 9.80±9.20        | 7.93±7.20          |

Data are presented as median (IQR) or mean±SD unless otherwise noted. CRP, C-reactive protein; PASI, psoriasis area and severity index.
Treatment also improved CRP levels relative to placebo. In contrast, less pronounced changes were observed in the placebo group.

Comparison of clinical endpoints between placebo and combined golimumab groups in the biomarker substudy

In the biomarker substudy, 6.5% of patients in the placebo group achieved ACR20 response at week 14, compared with 55.1% of patients in the combined golimumab group. In addition, a higher percentage (48.0%) of patients in the combined golimumab group achieved a PASI75 response at week 14 compared with patients in the placebo group (9.5%). Likewise, there was a greater decrease in the mean DAS score in the combined golimumab group compared with those in the placebo group, −1.47 and −0.11, respectively. Comparison of the substudy with the overall study population indicated comparable clinical benefit following golimumab treatment in each of these efficacy measures.10

Biomarker correlations with clinical endpoints

The biomarkers (baseline levels and change from baseline to week 4) were evaluated for association with ACR20, DAS28, and PASI75 at week 14 using a logistic regression analysis (table 2). Only biomarkers with a significant association to at least one of the clinical measures are shown. Baseline levels of adiponectin, prostatic acid phosphatase (PAP) and VEGF were significantly associated with two clinical endpoints, while no markers were significantly associated with all three measures. As shown in table 2, various other baseline markers were significantly associated with only one clinical measure. Interestingly, most of the identified markers were associated with DAS28, and relatively few correlated with ACR20 or PASI75.

Biomarker changes from baseline to week 4 were also correlated with clinical measures at week 14. A similar pattern was observed, there were more associations with DAS28 than with ACR20 or PASI75, and none of the markers correlated across all three endpoints. Only the change in cancer antigen 125, IL-16, PAP and serum glutamic oxaloacetic transaminase (SGOT) levels correlated with two clinical endpoints, although other analytes correlated with a single endpoint. ENRAGE, IL-16, myeloperoxidase, PAP and VEGF consistently correlated with ACR20 and/or DAS28 endpoints, with both baseline and change from baseline to week 4 biomarker results.

The placebo group had no significant associations between biomarkers and any clinical endpoints except for a correlation between change from baseline to week 4 in MIP-1β with DAS28 at week 14 (data not shown).

Biomarker prediction of clinical endpoints

Combined baseline biomarker panels were evaluated for their potential to predict clinical response at week 14 using a logistic regression model (table 3). Pyridinoline, adiponectin, PAP and factor VII were identified as a panel of markers that have the potential to be predictive of ACR20 response at week 14 (specificity 65%, sensitivity 85%). Similarly, adiponectin, factor VII, SGOT, IgA and leptin were identified as potentially predictive of DAS28 response (specificity 71%, sensitivity 90%). Adiponectin, factor VII and IL-16 indicated prediction of PASI75 response (specificity 65%, sensitivity 76%). Both adiponectin and factor VII appeared in the prediction models for all three clinical endpoints.

Figure 1  Heat map profile of serum markers in which the changes at week 4 or 14 were significantly different in patients treated with golimumab versus placebo. IL, interleukin; ICAM, intercellular adhesion molecule; MCP, monocyte chemotactic protein-1; MDC, macrophage-derived chemokine; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; PAI-1; plasminogen activator inhibitor 1; VEGF, vascular endothelial growth factor.
The data for CRP as a single analyte are shown for comparison to the biomarker panels as well as to the individual markers identified in the predictive panels for ACR20, DAS28 and PASI75 at week 14. The predictive power of the biomarker panels was stronger than for CRP alone for each of the endpoints.

**DISCUSSION**

This biomarker study of GO–REVEAL showed that golimumab treatment is effective in modulating specific acute-phase reactants, inflammatory markers, metabolic factors, bone remodelling markers and other selected proteins compared with placebo. Due to the varied assessments used to measure improvement in PsA, it is not surprising that no individual marker significantly correlated with all three clinical measures. However, as shown in table 2, the odds ratios (OR) for several of the identified markers showed strong associations with two of the clinical measures (DAS28 and ACR20) at week 14.

In the current study, serum levels of a subset of proteins (apolipoprotein CIII, ENRAGE (S100A12), IL-6, myeloperoxidase, VEGF, pyridinoline, MMP-3, CRP, carinoembryonic antigen, ICAM-1 and MIP-1α) at baseline or week 4 were strongly associated with ACR20 and/or DAS28 scores at week 14. Several of these markers including CRP, VEGF, MMP-3 and ICAM-1 have been previously identified to correlate with clinical endpoints in RA following anti-TNF treatment, suggesting biological similarities in some disease processes, especially among PsA patients with polyarticular peripheral arthritis. In a recent study, levels of IL-6, VEGF, MMP-3 and YKL-40 were significantly associated with clinical response to anti-TNFα therapies in patients with spondyloarthropathies. In RA, high baseline levels of urinary pyridinoline/DPD ratio are predictive of joint damage and are thought to reflect alterations in the bone tissue matrix, and these markers might also have significance in PsA.

A few markers at baseline were significantly associated with PASI75 at week 14 including adiponectin, apolipoprotein CIII, SGOT and TNFα. In addition, both IL-6 and ENRAGE (S100A12) levels were strongly associated with DAS28 and/or ACR20 at week 14 in golimumab-treated PsA patients. Several of these markers have been identified to be of particular interest. IL-6 has been shown to be induced in synovial fibroblasts from RA patients, independent of nuclear factor κB signalling. In addition, IL-17 can increase levels of IL-16 messenger RNA by RA fibroblast-like synovocytes and peripheral blood mononuclear cells. Given the proposed role of IL-17 in spondyloarthropathies, it is possible that there is a synergy with IL-16 and IL-17 to perpetuate rheumatological disease processes. Elevated levels of ENRAGE (S100A12) have been observed in both tissue and peripheral blood of PsA patients and can be modulated by treatment with methotrexate. The associations observed with adiponectin are intriguing relative to the effect of obesity on clinical outcomes and response to therapy in several systemic inflammatory autoimmune conditions, including PsA. In RA, adiponectin levels correlate with disease severity. Also, coordinated roles for adiponectin, leptin and visfatin are suggested in the modulation of the inflammatory environment in patients with RA. It could be that these adipokines play a similar role in PsA and can be downregulated by TNF inhibition. Nevertheless, the available data regarding the effects of anti-TNF treatments on adiponectin levels in RA are often conflicting.

We also explored whether CRP alone or in a combination of markers could significantly predict clinical response to golimumab treatment in patients with PsA. In combination with other markers, CRP did not improve the prediction of clinical response over the biomarker panels identified without CRP. Different combinations of markers including, pyridinoline, adiponectin, PAP, factor VII, IL-6, SGOT, IgA and/or leptin were found to be predictive of ACR20, DAS28, or PASI75 response to golimumab treatment. Baseline levels of adiponectin and factor VII with other markers were significantly associated with all three evaluated clinical measures. The only markers identified as potential predictive markers for PASI75 response at week 14 were IL-16, adiponectin and factor VII. The sensitivity and specificity of these combinations were stronger than CRP alone in predicting clinical response.

**Table 2** Odds Ratios (OR) from robust logistic regression analysis testing the association between biomarker levels (baseline and change from baseline to week 4) and clinical endpoints with at least one significant association at week 14 in the golimumab group

| Biomarker     | ACR20 OR | DAS28 OR | PASI75 OR |
|---------------|----------|----------|-----------|
| Baseline      |          |          |           |
| Adiponectin   | 1.681 NS  | 2.296 0.019 | 1.969 0.035 |
| Apolipoprotein CIII | 0.865 NS | 1.459 NS | 2.397 0.048 |
| ENRAGE        | 1.133 NS  | 2.455 0.066 | 0.717 NS  |
| IgA           | 1.013 NS  | 1.849 0.023 | 1.279 NS  |
| IGF-1         | 1.234 NS  | 1.668 NS | 0.272 0.015 |
| IL-16         | 0.858 NS  | 2.330 0.028 | 1.063 NS  |
| Insulin       | 0.803 NS  | 0.706 0.018 | 0.876 NS  |
| Myeloperoxidase| 1.323 NS  | 1.743 0.019 | 0.720 NS  |
| PAP           | 2.528 0.034 | 2.761 0.021 | 0.927 NS  |
| SGOT          | 0.536 NS  | 0.274 0.001 | 1.471 NS  |
| VEGF          | 1.665 0.042 | 2.338 0.008 | 1.133 NS  |
| Pyridinoline  | 0.198 0.008 | 0.344 NS | 0.777 NS  |
| MMP-3         | 1.115 NS  | 1.264 NS | 0.509 NS  |
| Change from baseline to week 4 |          |          |           |
| CRP           | 0.708 0.038 | 0.700 NS | 0.851 NS  |
| Cancer antigen 125 | 0.286 0.034 | 0.293 0.046 | 0.929 NS  |
| Carcinoembryonic Antigen | 0.054 0.024 | 0.341 NS | 0.461 NS  |
| CD40          | 0.516 NS  | 0.265 0.040 | 2.217 NS  |
| CD40 ligand   | 0.773 NS  | 0.558 0.027 | 1.100 NS  |
| ENRAGE        | 0.589 0.029 | 0.622 NS | 1.319 NS  |
| ICAM-1        | 0.387 NS  | 0.178 0.028 | 2.280 NS  |
| IL-16         | 0.305 0.047 | 0.191 0.016 | 1.224 NS  |
| MDC           | 0.118 0.009 | 0.324 NS | 0.233 NS  |
| MIP-1α        | 0.976 NS  | 0.319 0.015 | 1.033 NS  |
| MIP-1β        | 0.544 NS  | 0.127 0.009 | 0.899 NS  |
| Myeloperoxidase| 0.806 NS  | 0.589 0.014 | 1.077 NS  |
| PSA-free      | 0.343 NS  | 0.167 0.025 | 0.604 NS  |
| PAP           | 0.220 0.009 | 0.144 0.003 | 1.243 NS  |
| SGOT          | 1.150 NS  | 2.251 0.040 | 0.459 0.044 |
| TNF receptor II | 0.158 NS | 0.090 0.032 | 0.500 NS  |
| VEGF          | 0.395 NS  | 0.196 0.009 | 1.836 NS  |
| TNFα serum    | 0.592 NS  | 0.400 NS | 0.039 <0.001 |
| ICAM-1        | 0.055 0.044 | 0.235 NS | 0.428 NS  |

Values were significant if they were p<0.05.

ACR20, American College of Rheumatology 20% improvement response; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ICAM, intercellular adhesion molecule; IL, interleukin; IgA, immunoglobulin A; MDC, monococyte/macrophaage-derived chemokine; MIP-1, macrophage inflammatory protein 1; MMP, matrix metalloproteinase; NS, not significant; PAP, prostatic acid phosphatase; PSA, prostate-specific antigen; PASI75, 75% improvement in the psoriasis area and severity index score; SGOT, serum glutamic oxaloacetic transaminase; TNF, tumour necrosis factor; VEGF, vascular endothelial growth factor.

Copyright.

Ann Rheum Dis 2013;72:83–88. doi:10.1136/annrheumdis-2012-201697

Published online as 10.1136/annrheumdis-2012-201697 on September 17, 2013.
This analysis identified several panels of markers that may be predictive of ACR20, DAS28, or PASI75 responses. The goal of including this broad panel of markers was to evaluate potential new markers not previously known for their associations with PsA disease or TNF-mediated disease processes. Although these analyses included nearly 100 markers for comparison with clinical efficacy measures, there may well be other analytes that could show even stronger correlations, including some that indicate disease healing or repair. It is not surprising that different panels of markers were identified given the unique information captured in these clinical assessments evaluating either skin or joint involvement. As this was a hypothesis-generating evaluation of a panel of markers that may be predictive, it is recognised that these observations would need to be confirmed in an independent study. However, these results can provide a valuable foundation for subsequent biomarker comparisons in the PsA population. Insights from this study have suggested new combinations of markers that may have utility in understanding the relevance of changes in the inflammatory processes that occur in the skin and joints of PsA patients in response to golimumab treatment.

### Table 3 Logistic regression model comparing baseline CRP and baseline combined biomarker panels in predicting clinical response to golimumab treatment at week 14

| Model (true/predicted)† | ACR20* response | DAS28† response | PASI75* response |
|-------------------------|-----------------|-----------------|------------------|
| **Baseline biomarker panel†** | **ACR20** | **DAS28** | **PASI75** |
| Non-responder | NR | R | Accuracy† | NR | R | Accuracy† | NR | R | Accuracy† |
| Responder | 26 | 14 | Sensitivity: 65% | 17 | 7 | Specificity: 71% | 31 | 18 | Specificity: 63% |
| Predictive value | NPV 84% | PPV 67% | NPV 77% | PPV 87% | NPV 84% | PPV 51% |
| **Baseline CRP only†** | | | | |
| Non-responder | 28 | 12 | Specificity: 70% | 17 | 7 | Specificity: 71% | 21 | 28 | Specificity: 43% |
| Responder | 23 | 11 | Sensitivity: 32% | 25 | 25 | Sensitivity: 50% | 11 | 14 | Sensitivity: 56% |
| Predictive value | NPV 55% | PPV 48% | NPV 40% | PPV 78% | NPV 66% | PPV 33% |
| Predictive panel† | Weight | OR | p Value | Weight | OR | p Value | Weight | OR | p Value |
| Pyridoxine | –1.89 | 0.15 | 0.009 | – | – | – | – | – | – |
| Adiponectin | 1.00 | 2.72 | 0.010 | 1.19 | 3.29 | 0.015 | 0.69 | 1.99 | 0.046 |
| Prostate acid Phosphatase | 1.51 | 4.53 | 0.011 | – | – | – | – | – | – |
| Factor VII | –0.76 | 0.47 | 0.039 | 1.25 | 3.49 | 0.038 | 0.73 | 2.08 | 0.043 |
| IL-16 | – | – | – | – | – | – | –1.75 | 0.17 | 0.006 |
| SGOT | – | – | – | –2.07 | 0.13 | 0.001 | – | – | – |
| IgA | – | 0.92 | 0.51 | 0.92 | 2.51 | 0.010 | – | – | – |
| Leptin | – | – | – | –0.86 | 0.52 | 0.016 | – | – | – |

*ACR20, PASI75 and DAS-28 were treated as categorical variables in this analysis. To be classified as a DAS28 responder, patients had to have a good or moderate response.10
†All biomarker values were log10-transformed before inclusion in the models.
‡Model accuracy (sensitivity, specificity, NPV, PPV) was estimated using cross-validation.
#Weights are the coefficients in the logistic regression model. OR are the exponential of the weights. Multivariate p values are based on inclusion of all terms in the model.
ACR20, American College of Rheumatology 20% improvement response; CRP C-reactive protein; DAS28, disease activity score in 28 joints; Ig, immunoglobulin; IL, interleukin; NPV, negative predictive value; NR, non-responders; PASI75, 75% improvement in the psoriasis area and severity index score; PPV, positive predictive value; R, responders; SGOT, serum glutamic oxaloacetic transaminase.

Acknowledgements The authors thank the patients, investigators and study personnel who made the GO–REVEAL study possible. The authors also thank Mary Whitman, PhD, and Kirsten Schuck of Janssen Services, LLC, for writing and editing support.

Funding This study was supported by Janssen Research & Development, LLC, Spring House, PA, USA and Merck/Schering-Plough, Kenilworth, NJ, USA.

Competing interests ME served as a paid consultant for the study sponsor. IBMi has received grant support and honoraria from MSD. PJM has received grant support, consulting fees, and/or speaker fees from Janssen, Abbott, Amgen, BMS, Pfizer, Lilly, Genentech, Roche, BiogenIDEC, Novartis and UCB. GJK has received fees as a consultant or advisory board member for Abbott, Amgen, Anacor, ApoPharma, Astellas, Boehringer Ingelheim, Bristol Meyers Squibb, Janssen, ConbratoPhx, Genentech, Genzyme, Idera, Isis, Lilly, L’Oréal, MedaCorp, Medicis, Novartis, NovoNoridisk, Pfizer, Schering Plough, Somagenics, Synvista, Vascular Bioligics Ltd and UCB. In the past 24 months, GJK has received lecture fees from Abbott, Amgen, Astellas, Janssen, National Psoriasis Foundation and the Foundation for Better Health Care. GJK has received partial stipend support for a clinical research fellowship from Abbott, Amgen and Janssen. KP has served as a consultant for Abbott, Amgen, Astellas, Celgene, Eli Lilly, Janssen, Janssen Biotech, Johnson & Johnson, Merck, Novartis, Pfizer and UCB. KP has been on speaker’s bureaus for Amgen, Astellas, Janssen, Merck, Novartis and Pfizer. KP has received clinical research grants from Abbott, Amgen, Anacor, Astellas, Celgene, Genentech, Dow Pharma, Eli Lilly, Galdenira, Janssen, Janssen Biotech, Merck and Novartis. He has served on advisory boards for Abbott, Amgen, Celgene, Janssen, Janssen Biotech, Merck, Novartis and Pfizer. JGR is on the advisory boards of BMS, Pfizer, Roche, Schering Plough and UCB SA, has received lecture fees from BMS, Roche, Schering Plough and Wyeth, and has received research grants from Roche and Schering-Plough. CW, SV, MM and AB were all employees of Janssen Research & Development, LLC at the time of the study and own stock/stock options in Johnson & Johnson. DDS has received research support from Abbott, Amgen, BMS, Janssen, Pfizer and UCB. AK has received consultancy fees, speaking fees and/or honoraria from Janssen. FTM has no conflicts of interest.

Ethics approval Institutional review board or ethics committee approval and patient written informed consent were obtained before study participation.

Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES

1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcomes. Ann Rheum Dis 2005; 64(Suppl. 2):i34–17.

2. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003; 14:241–9.

3. van Kuijk AW, Reinders-Blankert P, Smets TJ, et al. Detailed analysis of the cell infiltrates and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006; 65:1551–7.

4. van Kuijk AW, Wijbrandts CA, Winkens M, et al. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis 2010; 69:301–4.

5. Xia L, Shen H, Xiao W, et al. Increased serum TWEAK levels in Psoriatic arthritis: relationship with disease activity and matrix metalloproteinase-3 serum levels. Cytokine 2011; 53:289–91.

6. Ribbens C, Martin y Porras M, Franchinont N, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 2002; 61:161–6.

7. van Kuijk AW, DeGroot J, Koeman RC, et al. Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. PLoS One 2010; 5:e12556.

8. Grisar J, Bernecker PM, Aigner M, et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002; 29:1430–6.

9. Dalbeth N, Pool B, Smith T, et al. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res Ther 2010; 12:R164.

10. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60:976–86.

11. Wagner C, Visvanathan S, Braun J, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann Rheum Dis 2012; 71:674–80.

12. Visvanathan S, Rahman MU, Keystone E, et al. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the G0–FORWARD study. Arthritis Res Ther 2010; 12:R211.

13. Pedersen SJ, Hetland ML, Sorensen U, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. Clin Rheumatol 2010; 29:1301–9.

14. Hashimoto J, Gamero P, van der Heijde D, et al. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. Mod Rheumatol 2006; 19:273–82.

15. Hashimoto J, Gamero P, van der Heijde D, et al. Humanized anti-interleukin-6 receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol 2011; 21:10–15.

16. Warstuk K, Hoberg M, Rudert M, et al. Transforming growth factor beta1 and laminin-111 cooperate in the induction of interleukin-16 expression in synovial fibroblasts from patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:270–5.

17. Cho ML, Jung YD, Kim KW, et al. IL-17 induces the production of IL-16 in rheumatoid arthritis. Exp Mol Med 2008; 40:237–45.

18. Noordens T, Kremerskoen N, Gutfía I, et al. Interleukin-17 positive mast cells contribute to synovial inflammation in spondyloarthritis. Arthritis Rheum 2012; 64:99–109.

19. Foell D, Kane D, Bresnihan B, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003; 42:1383–9.

20. Gomez R, Conde J, Scotece M, et al. What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 2011; 7:529–36.

21. Otero M, Lugo R, Gomez R, et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1198–201.